These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 1752152)
1. [Prospective study of functional changes in the gallbladder and formation of gallstones induced by long-term treatment of somatostatin analogue SMS201-995 in patients of active acromegaly]. Zhu XF; Shi YF; Zhang JX Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):405-8, 455. PubMed ID: 1752152 [TBL] [Abstract][Full Text] [Related]
2. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099 [TBL] [Abstract][Full Text] [Related]
3. [Acute effect of small dosages of somatostatin analogue SMS201-995 on gallbladder contractility in normal adults]. Zhu X Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Jun; 14(3):201-5. PubMed ID: 1394739 [TBL] [Abstract][Full Text] [Related]
4. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly. Ewins DL; Javaid A; Coskeran PB; Shah S; Butler J; Deprez PH; Miell J; Calam J; Barrett JJ; Dawson JM Q J Med; 1992 Apr; 83(300):295-306. PubMed ID: 1631261 [TBL] [Abstract][Full Text] [Related]
5. A prospective examination of octreotide-induced gall-bladder changes in acromegaly. Eastman RC; Arakaki RF; Shawker T; Schock R; Roach P; Comi RJ; Gorden P Clin Endocrinol (Oxf); 1992 Mar; 36(3):265-9. PubMed ID: 1563079 [TBL] [Abstract][Full Text] [Related]
6. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients. Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435 [TBL] [Abstract][Full Text] [Related]
15. Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment. Rhodes M; James RA; Bird M; Clayton B; Kendall-Taylor P; Lennard TW Scand J Gastroenterol; 1992; 27(2):115-8. PubMed ID: 1561523 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide. Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918 [TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. Plöckinger U; Dienemann D; Quabbe HJ J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321 [TBL] [Abstract][Full Text] [Related]
18. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128 [TBL] [Abstract][Full Text] [Related]
19. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Hussaini SH; Murphy GM; Kennedy C; Besser GM; Wass JA; Dowling RH Gastroenterology; 1994 Nov; 107(5):1503-13. PubMed ID: 7926514 [TBL] [Abstract][Full Text] [Related]
20. Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course. Avila NA; Shawker TH; Roach P; Bradford MH; Skarulis MC; Eastman R J Clin Ultrasound; 1998; 26(6):289-94. PubMed ID: 9641388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]